key: cord-0836940-w4i0q6rm
authors: Battisti, Nicolò Matteo Luca; Mislang, Anna Rachelle; Cooper, Lisa; O'Donovan, Anita; Audisio, Riccardo A.; Cheung, Kwok-Leung; Sarrió, Regina Gironés; Stauder, Reinhard; Soto-Perez-de-Celis, Enrique; Jaklitsch, Michael; Williams, Grant R.; O'Hanlon, Shane; Alam, Mahmood; Cairo, Clarito; Colloca, Giuseppe; Gil, Luiz Antonio; Sattar, Schroder; Kantilal, Kumud; Russo, Chiara; Lichtman, Stuart M.; Brain, Etienne; Kanesvaran, Ravindran; Wildiers, Hans
title: Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group
date: 2020-07-16
journal: J Geriatr Oncol
DOI: 10.1016/j.jgo.2020.07.008
sha: fcca84a57963a913516bd6df17e5eb4474a6ba63
doc_id: 836940
cord_uid: w4i0q6rm

Abstract The COVID-19 pandemic poses a barrier to equal and evidence-based management of cancer in older adults. The International Society of Geriatric Oncology (SIOG) formed a panel of experts to develop consensus recommendations on the implications of the pandemic on several aspects of cancer care in this age group including geriatric assessment (GA), surgery, radiotherapy, systemic treatment, palliative care and research. Age and cancer diagnosis are significant predictors of adverse outcomes of the COVID-19 infection. In this setting, GA is particularly valuable to drive decision-making. GA may aid estimating physiologic reserve and adaptive capability, assessing risk-benefits of either providing or temporarily withholding treatments, and determining patient preferences to help inform treatment decisions. In a resource-constrained setting, geriatric screening tools may be administered remotely to identify patients requiring comprehensive GA. Tele-health is also crucial to ensure adequate continuity of care and minimize the risk of infection exposure. In general, therapeutic decisions should favor the most effective and least invasive approach with the lowest risk of adverse outcomes. In selected cases, this might require deferring or omitting surgery, radiotherapy or systemic treatments especially where benefits are marginal and alternative safe therapeutic options are available. Ongoing research is necessary to expand knowledge of the management of cancer in older adults. However, the pandemic presents a significant barrier and efforts should be made to ensure equitable access to clinical trials and prospective data collection to elucidate the outcomes of COVID-19 in this population.

The COVID-19 pandemic requires the implementation of individualized approaches for the management of cancer in older adults. As of June 2020, there were more than 10 million cases and over 500,000 deaths worldwide.[1, 2] The actual cumulative death toll from COVID-19 is expected to be higher as reporting varies within each country. While the virus affects people of all ages, data have consistently shown that mortality is higher with increasing age and comorbidities. [3] [4] [5] [6] The case fatality rates (CFR) in patients aged less than 70 years were reported as 0.3-3.5%. [7, 8] This is in contrast to the CFR of 8% in patients aged 70-79 years and around 15% in those aged over 80 years in China. [7] In Italy, epidemiological data shows that the mean age of patients dying from COVID-19 was 80 years, [9] with CFR rising with increasing age beyond 70 years: 12.5% (70) (71) (72) (73) (74) (75) (76) (77) (78) (79) , 19.7% (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) and 22 .7% (over 90). [8] In the United States, the death rate in New York City among patients aged 75 years or older was more than 1,511 per 100,000 population[10].

COVID-19 represents an additional competing risk factor to consider when undertaking therapeutic decisions for older adults with cancer ( Figure 1 ). The

International Society for Geriatric Oncology (SIOG) advocates for intergrating geriatric assessment (GA) to drive decision-making in the management of older adults with cancer, especially during the COVID-19 pandemic. .

Older age and comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, chronic renal impairment, and cancer have been shown to increase risk for worse outcomes from COVID-19. [11, 12] In many older patients with cancer where management could be challenging, the risks of morbidity and mortality from acquiring COVID-19 must be considered when assessing risks and benefits of the decision to treat. Currently, personalized care should be the norm in treating older patients with cancer; with COVID-19, it becomes even more imperative that such an approach is followed to avoid the risk of over-or under-treatment [13] and minimize the risk of adopting an ageist approach.

In order to mitigate the negative impact of COVID-19 on the management of cancer in older adults. SIOG has brought together a COVID-19 Working Group including J o u r n a l P r e -p r o o f Journal Pre-proof members from different continents and with different specialties (surgery, radiation oncology, medical/geriatric oncology, geriatrics, hematology, nursing, pharmacy) to develop recommendations and an action plan based on expert opinion and evidence related to geriatric oncology and applied to these circumstances.

Cancer is a disease of older adults. On the other hand, baseline information from epidemiological data on specific cancer types, stage, and treatment at the time of COVID-19 infection are lacking. In the recently published COVID-19 and Cancer Consortium (CCC19) cohort, the median age of patients with cancer and COVID-19 was 66 years, and 56% were aged 65 years and older. [14] Mortality was found to be closely associated with age, with patients aged 65-74 and over 75 years having a relative risk of death of 11% and 25% respectively, compared to 6% for patients below the age of 65 years. In the TERAVOLT cohort of patients with thoracic malignancies and COVID-19, age was also closely associated with increased risk of death, with patients aged 65 years and older (OR 1.88, 95% CI 1.0-3.6). [15] In general, COVID-19 is acquired by transmission of a respiratory virus via close contact, droplet spray or aerosol, with the duration of viral stability and viability maintained depending on various objects or surfaces. [ Several geriatric-focused issues have been identified as a result of imposed quarantine and social distancing, including: 1) feelings of estrangement and neglect due to limited access to news or information, friends and family, particularly when access to digital technology is lacking; 2) decline in communication and comprehension not only due to isolation but also from wearing masks and face shields, more particularly so for hard-of-hearing patients who rely on lip reading and non-verbal cues; 3) loss of autonomy and ensuing dependency on others to provide basic needs such as medicines, food and other home supplies due to travel restrictions or lack of access to transportation; 4) disruption of established community support for seniors such as cleaning, shopping, and home maintenance to aid them to cope with daily life; 5) increased risk of deconditioning in the outpatient setting and following acute medical admissions. In addition, social restrictions and shielding can lead to significant decrease in physical activity which, in turn, can contribute to or accelerate loss of muscle mass and bone density, as well as mobility and functional impairment in older adults; [18, 19] and 6) institutionalized patients, such as those in a nursing care facility are at higher risk of acquiring COVID-19 infection, increased feelings of abandonment, as well as mental health problems. [20, 21] The risk of delirium is especially important and underestimated, called by some experts the "silent epidemic within the pandemic." [22, 23] Leading authorities on delirium have found that altered mental status may be one of the first signs of COVID-19 infection among vulnerable older adults, and that the current state of hospitals and other healthcare settings is becoming more "deliriogenic" as they restrict visitors, require all staff members to wear personal protective equipment (PPE), and minimize patient interaction to avoid exposure. [24] In these times, it is paramount to evaluate in the out-patient setting and stratify the risk of delirium in patients prior to administering any anticancer therapy. Hence, the impact of social isolation as a result of recommendations on physical distancing, risk of delirium, and decisions regarding anticancer treatment are important issues to assess and proactively address. [25] J o u r n a l P r e -p r o o f Journal Pre-proof

Older patients with underlying comorbidities have increased disease severity and mortality from COVID-19. [26] Chronological age alone should not drive decisions on whether or not to provide life-saving treatments during the pandemic, [27] and yet, older patients with cancer are likely to be doubly disadvantaged as health systems are overwhelmed.

Prior to this pandemic, frailty had been increasingly adopted as a superior predictor of adverse outcomes over chronologic age for older adults in multiple clinical settings. In the oncology setting, frailty has been proven to predict toxicity from treatment and mortality, and leading cancer societies have recommended GA to gauge frailty prior to treatment in older adults to assess such risks. [28] [29] [30] The decision to treat older patients with cancer is best guided with GA and discussed in a multidisciplinary setting to help care providers determine the best treatment options, predict treatment-related toxicities, and establish ongoing management for cancer and other competing risks. [31] GA is particularly valuable in a context where competing risks are more prevalent. GA may estimate physiologic reserve and adaptive capability, assess risk-benefits of either providing or temporarily withholding treatments, and determine patient preference to help inform treatment decisions.

Different tools, such as the Clinical Frailty Scale and the Frailty Index have been proposed to screen and stratify frailty in the setting of COVID-19. [32, 33] However, others have highlighted that their use has not been validated in these circumstances, and advocate for cautious implementation in the context of the pandemic as clear evidence is limited. [34, 35] Additional concerns about the widespread use of these tools include the need for standardized training to ensure accuracy in the assessment as well as a clear understanding of limitations and appropriateness of using these tools to inform, and not replace personalized discussions and care recommendations for older adults. In the majority of cases, in the interest of time to limit visits and infection exposure for professionals and patients, geriatric screening may be sufficient to identify the risk of frailty in some way. The selection of patients most likely to benefit from a multi-domain GA is a major challenge.

We recommend using screening tools that can be self-administered by patients, such as the G8 screening tool or Vulnerable Elders-13 Survey (VES13). [36] Once patients are identified as high-risk for frailty, we recommend further assessment by clinicians with geriatric expertise via telemedicine for assessment of function, cognitive reserve, mood and delirium, nutritional status, and social support using validated tools.

Telehealth has been implemented widely across settings in the midst of the current pandemic, and has been shown to be an effective modality [37] even for vulnerable populations. [38] Oncology-specific GA can also be conducted via telemedicine. One example was outlined by the University of Rochester Specialized Oncology Care and Research in the Elderly (SOCARE) and the Ohio State University group. They presented a framework for multi-domain GA that can be conducted mostly by telephone. This telemedicine version of the GA includes a pre-visit phone screen to identify areas of vulnerability and help guide decision-making for older adults with cancer (Table 1 . [39] More research on conducting GA in a time-efficient manner is needed and decisionmaking should incorporate patients' preferences and goals, especially in these times of heightened risk and uncertainty. Paired with the information derived from a GA, goal-concordant care is paramount in partnership with patients and caregivers in weighing the risks of COVID-19 exposure and anticancer treatments against the risks of delaying such treatment.

Decision-making should be individualized and take into account the potential risk of pursuing, delaying or omitting surgery or choosing different surgical approaches.

( Table 2 ). For example, open and endoscopic techniques have different intensive care requirements, whereas some operations may avoid or delay the need of alternative treatments (e.g., neoadjuvant chemotherapy) which may be less safe in the context of the pandemic. Along with patients' fitness and comorbidities that may influence postoperative outcomes, clinicians should consider factors related to the J o u r n a l P r e -p r o o f tumor, such as its morbidity and mortality and the presence or absence of ongoing cancer-related symptoms, and those associated with the planned surgical procedure being considered, in order to ensure the most secure and safest approach to achieve local disease control.

Elective surgical procedures scheduled at inpatient facilities may be delayed. [40, 41] Nonetheless, the definition of "elective" is sometimes debatable. Apart from emergency operations, any essential procedures may include those where a delay by two or three months can significantly impact on outcomes and/or those where surgery is a crucial component of cancer management, such as for breast, colon, gastric, pancreatic, liver, bladder, renal, lung and brain tumors. [42, 43] Selected procedures aiming for rapid symptomatic relief and minimizing neurological complications should also be prioritized. Surgical management of non-invasive tumors, such as breast ductal in-situ carcinoma, can also be delayed since they are unlikely to impact on survival outcomes in this age group.

The risk of tumor progression with delayed radical surgery should also be balanced with the availability of resources. These include the availability of operating theatres that may been converted to intensive care units (ICUs), the local ICU and anesthetist capacity, the risk of surgical complications, and the expected recovery time. [44] The presence of pre-existing lung conditions that can increase the risk of complications should also be considered, along with the need to perform aerosol-generating procedures. For patients who require surgery, measures should be put in place to mitigate risks, such as preoperative testing and isolation, use of PPE and cohorting operations in COVID-19-free areas.

An observational study of 1,128 patients undergoing surgery and who had a confirmed COVID-19 infection within 7 days before or 30 days after the procedure reported more than 2-fold increase in 30-day mortality for those aged 70 and older (OR 2.30).

[45] Consequently, the most effective surgical procedures with minimal invasiveness, least post-operative morbidity, and fastest recovery time should be prioritized in this age group.

Delaying surgery may be appropriate for selected older patients while monitoring the cancer behaviour until the outbreak is under control. For example, a 60-day delay to surgery for stage I-II breast cancer patients had no detrimental impact on outcomes in a retrospective analysis from a single academic hospital. [46] Less toxic systemic treatment such as endocrine therapy or radiotherapy may be considered means to delay surgery in selected cases, as discussed below. Nonetheless, predicting when the outbreak will end, even at a local level remains a significant challenge.

As surgery gets delayed, prehabilitation may be adopted during pandemic to ensure that fitness to treatment is achieved or maintained while waiting, to minimize post-op morbidity and mortality, which may include physical exercise, nutritional support, as well as management of comorbidities, health risks and psychosocial factors. [47] However, such intervention should be implemented in the context of the recommended strategies to minimize the risk of COVID-19 transmission.

In certain circumstances, omitting surgery may be appropriate when the impact on symptoms and survival is minimal or if a safe and effective alternative systemic treatment is available. For example, the use of primary endocrine therapy for older patients with early-stage ER-positive, HER2-negative breast cancer is supported by evidence demonstrating no positive impact of surgery on overall survival (OS). [48] [49] [50] 

Similarly, the use of radiation therapy (RT) in older patients should be prioritized based on its intent, expected benefits, and tumor characteristics in the context of patients' fitness and preference ( compared with a standard regimen of 40 Gy in 15 fractions. [53] Modest hypofractionation can also be considered for patients with early prostate cancer. [54] Such regimens are appropriate alternatives to minimize the risk of infection exposure in older patients. Despite its role still being debated, intraoperative RT may be considered to spare older adults undergoing surgery from having subsequent outpatient appointments. [55, 56] Specific guidance is available on RT regimens for patients with hematological malignancies. [57] In the palliative setting, patients should be offered the smallest number of fractions to minimize the need to attend the hospital and potential exposure to infection. For bony pain relief, a single 8 Gy fraction should be favored as equally effective as multiple fractions.

[58] A single fraction also can be offered in case of metastatic cord compression. [59] The role of whole brain RT for the management of brain metastases remains controversial as medical treatments might already be beneficial with regard to symptom control. [60] In contrast, stereotactic body RT (SBRT) might still be appropriate in the context of its better safety profile, which is particularly relevant in frail and older individuals. [61] RT should be delayed in the absence of any significant impact on cancer For patients with early-stage breast cancer, RT can be safely delayed for up to five months for those receiving chemotherapy followed by endocrine therapy. [64] RT can be delayed by 3-6 months for patients with early prostate cancer in case of low-risk J o u r n a l P r e -p r o o f disease while aiming for either active surveillance or upfront androgen deprivation therapy (ADT); [65, 66] in cases of high-risk disease, RT can be delayed for up to 2-3 months while starting patients on ADT. [67] In the curative setting, survival gains may be modest in older patients in the context of competing risks of mortality including COVID-19 and careful consideration should be given to balancing risks and benefits. Treatments reducing the risk of locoregional recurrence in the absence of any survival improvement may be appropriately omitted. [68] For older patients with low-risk disease, breast radiotherapy can be safely omitted. [69, 70] along with GA domains such as ability to take medications, physical activity and social activity. [76, 77] The Chemotherapy Risk Assessment Scale for High age (CRASH) is based on the specific chemotherapy regimen being considered as well as laboratory values (creatinine, albumin, hemoglobin, lactate dehydrogenase, liver function tests) and assessments of functional, mental, and nutritional status. [78] In the curative setting, chemotherapy should be considered if indicated and in the presence of clear survival benefits, which may be less established in the older age group. [79] If possible, a shorter treatment duration should also be considered. In the palliative setting, shared decision-making should also take into account the hazards of worsening symptoms and functional status, which may lead to losing the opportunity to treat. [80] Discontinuing chemotherapy may be an option for some patients with low volume disease or after attaining ongoing disease, especially if alternative non-myelosuppressive agents are available, such as endocrine therapy for hormone receptor-positive breast cancer patients.

In general, evidence-based chemotherapy regimens that require less frequent dosing should be favored in order to minimize the need for hospital attendance, In older patients with hematological malignancies, the risk of disease and treatmentrelated lymphopenia and neutropenia should also be considered and integrated in decision-making. [89] Likewise, the need for anti-CD20 monoclonal antibodies should be critically evaluated in view of the adverse impact of lymphopenia on COVID-19 outcomes. [90] Data are limited on the impact of immunotherapy on COVID-19 and potential risks and benefits should be balanced and personalized in older patients.

Nonetheless, the less frequent dosing of some immunotherapy agents is particularly attractive in this context to minimize the need for hospital visits. [91] Systemic treatment given in the adjuvant setting can be delayed within the accepted timing for each tumor type. For example, for patients with colorectal or lung cancer, it can be safely postponed for up to 8 weeks, [92, 93] and for those with breast cancer for up to 12 weeks after surgery. Systemic therapies may also be considered as effective means to delay surgery in selected cases. A neoadjuvant endocrine approach is particularly valuable for older patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, as aromatase inhibitors are associated with low toxicity and reasonable response rates at 3-4 months. [95] ADT may also be considered preoperatively for selected older adults with prostate cancer, although evidence on its impact on radical resection rates is still scarce. [96, 97] Despite the benefits, the use of upfront chemotherapy, e.g. taxanes, in the pandemic setting is more questionable in view of the higher risk of myelosuppression and infections in the older age group, the need for more hospital visits and clinician-patient contact, not unless the risks are outweighed by the benefits of rapid disease control to allow a curative resection, [85, 86, 98] although patients' preferences remain crucial. [99] Palliative care

Despite the scarcity of health resources brought on by the pandemic, attention needs to be paid for the provision and maintenance of palliative care services. COVID-19 restrictions and physical distancing guidelines have resulted in reduced access to available information, care and supports from families and friends, as well as social and personal care services that allow older persons, including those living with disabilities, to cope at home. Older persons with cancer may present with symptoms associated with their malignancy or treatment toxicity, exacerbation of comorbidities or COVID-19 that may require hospital admission for critical care and/or referral to palliative care.

Early discussion of advance care plans should be implemented to determine patients' preferences and treatment goals. Telemedicine can also facilitate communication with older adults in home settings and institutions as appropriate.

Clinicians should also ensure prompt and adequate communication with families and J o u r n a l P r e -p r o o f support older patients during end of life care in critical and palliative care setting, including psycho-social and spiritual support. Infection control procedures should apply also to palliative care settings. The demand for palliative care services (at home or residential care facilities, in hospitals or hospices) may increase and this should be adapted to respond rapidly and flexibly during the pandemic, [100] within the scope of availability of staff and other health-care resources.

Cancer survivors include people who have completed initial treatment with no evidence of active disease or those living with progressive disease who may be receiving cancer treatment but are not in the terminal phase of illness [101] . Older people account for more than two-thirds of cancer survivors [102] . However, COVID-19 may disproportionately impact older cancer survivors' physical health and psychosocial wellbeing, which may lead to unintended consequences in the longterm [103] . Despite social and outdoor activities being on hold due to COVID-19 restrictions, it is recommended to avoid sedentary lifestyle by maintaining physical activity by integrating exercise into the daily routine [104] .

Delivery of high-quality, tailored, person-centred survivorship care to address the unique needs of older cancer survivors during the pandemic is challenging.

Nonetheless, as evidence here is still lacking, the recommendations valid for the general population should apply also to older cancer survivors.

The COVID-19 pandemic presents a further major barrier to participation in clinical trials for older adults with cancer, who are already under-represented in oncology studies. [105] Screening and/or enrolment for certain clinical trials have been either halted or prioritized in several research programs worldwide. [106] Nonetheless, where feasible, it is imperative to continue facilitating the access of older patients to clinical trials to minimize the impact of the pandemic on the expansion of knowledge J o u r n a l P r e -p r o o f relevant for this age group while complying with current regulations and limiting the consequences on study integrity. [107, 108] The US Food and Drug Administration and the European Medicines Agency have issued specific recommendations on this topic. [109, 110] In addition, more evidence on the impact of the COVID-19 pandemic in older adults with cancer is warranted. With many preventive (i.e. COVID-19 vaccine) trials underway, inclusion of eligible older patients with cancer should be considered. As recently outlined by the CARG investigators, [25] multicenter and international collaborations and novel methods of rapid dissemination will be crucial to elucidate the interaction between global health measures (rather than age alone) and oncological outcomes, along with endpoints particularly meaningful for older adults, such as function and quality of life.

COVID-19 is an emerging and rapidly evolving condition that warrants tailored care and assessment depending on the disease prevalence. As society grapples with the pandemic and how best to deliver cancer care in older patients, there is an urgent need to act now to protect the vulnerable and mitigate the projected negative outcomes in this age group. As this is unlikely to be the last pandemic that we will encounter, it is imperative to take this unique opportunity to learn and devise management plans for both present and future use. It should also be acknowledged that the previously mentioned recommendations may lead to different implementation depending on the stage of the pandemic. Whilst data are still emerging and median follow-up from published trials is short to make robust conclusions, the SIOG Working Group has developed a number of recommendations on the management of older adults with cancer and future directions, which are outlined in Table 2 . J o u r n a l P r e -p r o o f 2) About how long ago was your most recent fall?

1) Do you experience fatigue and weakness?

2) If yes, rate your fatigue on a scale of 1-10 (10 = severe, 0 = absence).

Hearing 1) How is your hearing (with a hearing aide, if needed)?

2) If hearing is fair to totally deaf, how much does it interfere with activities? 2) What is your weight now?

3) What was your weight 6 months ago?

Social support 1) Who do you live with?

2) Who is your main social support? J o u r n a l P r e -p r o o f 

Novel Coronavirus (COVID-19) Situation

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Coronavirus Disease 2019 (COVID-19) in Italy

Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on May 28th, 2020. 2020. 10. Death rates for COVID-19 in

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet Oncology

Ageing and COVID-19: What is the Role for Elderly People?

Neurologic Features in Severe SARS-CoV-2 Infection

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Delirium: a missing piece in the COVID-19 pandemic puzzle

Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Natural disaster and rationing of care

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology

Frailty as determined by a comprehensive geriatric assessmentderived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer

Frailty Index Developed From a Cancer-Specific Geriatric Assessment and the Association With Mortality Among Older Adults With Cancer

Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology

COVID-19 rapid guideline: critical care in adults 2020, National Institute for Health and Care Excellence

Frailty index predicts poor outcome in COVID-19 patients

COVID-19: Use of the Clinical Frailty Scale for Critical Care Decisions

Decision-Making in COVID-19 and Frailty

Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations †

Virtually Perfect? Telemedicine for Covid-19

Telemedicine in the Time of Coronavirus

Development of a telehealth geriatric assessment model in response to the COVID-19 pandemic

Cancer Surgery and COVID19

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Timing of Breast Cancer Surgery-How Much Does It Matter?

Prehabilitation May Help Mitigate an Increase in COVID-19 Peripandemic Surgical Morbidity and Mortality

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)

A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up

A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up

International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet

Conventional versus hypofractionated high-dose intensitymodulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The Lancet Oncology

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. The Lancet

Update on intraoperative radiotherapy: new challenges and issues. Ecancermedicalscience

ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. The Lancet

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry

Cancer and COVID-19 -potentially deleterious effects of delaying radiotherapy

COVID-19 rapid guideline: delivery of radiotherapy. NICE guideline [NG162]. 2020, National Institute for Health and Care Excellence (NICE)

Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy

Final Report of Multicenter Canadian Phase III Randomized Trial of 3 Versus 8 Months of Neoadjuvant Androgen Deprivation Therapy Before Conventional-Dose Radiotherapy for Clinically Localized Prostate Cancer

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy

COVID-19: Global radiation oncology's targeted response for pandemic preparedness

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343

The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer-a meta-analysis of randomized trials

Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

COVID-19: Global radiation oncology's targeted response for pandemic preparedness. Clinical and Translational Radiation Oncology

Meeting the challenges imposed by COVID-19: Guidance document by the ESTRO Radiation TherapisT Committee (RTTC). Technical Innovations & Patient Support in Radiation Oncology

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience

Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer

Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer

Use and outcomes of adjuvant chemotherapy in older women with breast cancer

Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer

The outcome of combined-modality therapy for stage III non-smallcell lung cancer in the elderly

Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity

Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis

Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109

Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII

Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians

Policy Brief: The Impact of COVID-19 on older persons

Two million reasons -the Cancer Survivorship Agenda: Why we need to support people with or beyond cancer

Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States

Addressing the needs of cancer survivors during the COVID-19 pandemic

Stay physically active during self-quarantine

Under-representation of older adults in cancer registration trials: known problem, little progress

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an

Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic

Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards. 2020, Food and Drug Administration

Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic